Clinical Research Directory
Browse clinical research sites, groups, and studies.
Programmed Death-Ligand1 Expression in Her-2 Positive and Triple Negative Breast Cancer
Sponsor: Ain Shams University
Summary
Patients with Her-2 positive and triple negative breast cancer who received neoadjuvant chemotherapy will be included in the study. Paraffin blocks of preoperative core or tru-cut biopsies of the participants will be collected and tested for programmed death-ligand 1 (PD-L1) expression. The variation of PD-L1 expression among different breast cancer subtypes will be evaluated and the investigator will correlate between PD-L1 expression and pathological complete response to neoadjuvant systemic therapy.
Official title: Correlation Between Programmed Death-Ligand1 Expression and Clinical Outcomes After Neoadjuvant Systemic Therapy in Her-2 Positive and Triple Negative Breast Cancer
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
80
Start Date
2022-01-01
Completion Date
2024-10-30
Last Updated
2024-08-20
Healthy Volunteers
Yes
Locations (1)
Ain Shams University Clinical Oncology Department
Cairo, Abbasseya, Egypt